Press Release Archive

Here you will find past press releases; the archive can be searched by date alone or by both date and keyword.

View Press Releases

By Keyword

By Date

08.30.2010 - Forest Laboratories, Inc. and Gedeon Richter Plc Announce Results from a Phase II Study of Cariprazine for the Treatment of Bipolar Depression
07.22.2010 - Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KGaA Settle NAMENDA(R) Patent Litigation
07.20.2010 - Forest Laboratories, Inc. Reports First Quarter FY 2011 EPS of $0.39, Including $0.39 Per Share Charge Related to Settlement in Principle with US Department of Justice and $0.17 Per Share Charge for New Product Licensing Fee
07.07.2010 - Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2011 First Quarter Earnings
06.28.2010 - Forest Laboratories, Inc. and Gedeon Richter Announce Results from a Phase II Study of Radiprodil for the Treatment of Diabetic Peripheral Neuropathic Pain
06.21.2010 - Forest and Merz Announce FDA Approval of NAMENDA XR for the Treatment of Moderate to Severe Dementia of the Alzheimer's Type
06.09.2010 - Forest Laboratories, Inc. Announces Accelerated Share Repurchase
06.08.2010 - Forest Laboratories and TransTech Pharma Enter Into License Agreement for the Development and Commercialization of Glucokinase Activators with Deal Valued at Up to $1.105 Billion
05.18.2010 - Forest Laboratories, Inc. Announces New Share Repurchase Program
05.17.2010 - Forest Laboratories and Nycomed Receive Complete Response Letter for Roflumilast
05.11.2010 - Forest and Almirall to Present Data from Studies of Aclidinium Bromide in Chronic Obstructive Pulmonary Disease (COPD) and LAS100977 in Asthma
05.10.2010 - Forest and Nycomed to Present Results from Six Roflumilast Posters
05.03.2010 - New Data Demonstrate Efficacy and Tolerabilty of Bystolic(R) (Nebivolol) Tablets among Hispanics with Hypertension
05.03.2010 - Ironwood and Forest Present Positive Linaclotide Results from Two Pivotal Phase 3 Trials in Patients with Chronic Constipation
04.26.2010 - Ironwood and Forest to Present Linaclotide Phase 3 Chronic Constipation Data
04.20.2010 - Forest Laboratories, Inc. Reports Fiscal Year Fourth Quarter 2010 Earnings Per Share of $0.07, Including a One-Time Charge Totaling $0.76 Per Share
04.01.2010 - Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2010 Fourth Quarter Earnings
02.23.2010 - Forest Laboratories Receives Decision from FDA for Supplemental New Drug Application for Bystolic(R)
01.19.2010 - Forest Laboratories, Inc. Reports Fiscal Third Quarter 2010 Earnings Per Share of $0.69, Including One-Time Charges Totaling $0.28 Per Share
01.07.2010 - Forest and Almirall Announce Positive Results from the ACCORD COPD I Phase III Study of aclidinium bromide in Chronic Obstructive Pulmonary Disease (COPD)
01.04.2010 - Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2010 Third Quarter Earnings